###begin article-title 0
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 1
###begin p 2
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author Contributions:</bold>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Author Contributions: ASF, DAW, IF, MPD, PT, and MPR designed the study. ASF and EP performed statistical analysis of the data. MPD enrolled patients. ASF, DAW, IF, MPD, PT, and MPR contributed to writing the paper. ASF, IF and MPR were coauthors of a successful grant application that secured funds to support the data analysis. SR and MLW developed assays for the SNP genotyping, performed the SNP genotyping experiments for the study, and analyzed the resulting scatterplots.
###end p 2
###begin article-title 3
Antiretroviral Therapy and Dyslipidaemia: Unlocking the Code
###end article-title 3
###begin article-title 4
Race/Ethnicity, Lipoproteins, and Antiretroviral Therapy
###end article-title 4
###begin title 5
Background
###end title 5
###begin p 6
###xml 109 114 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 586 591 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Protease inhibitors (PIs) are associated with hypertriglyceridemia and atherogenic dyslipidemia. Identifying HIV-1-infected individuals who are at increased risk of PI-related dyslipidemia will facilitate therapeutic choices that maintain viral suppression while reducing risk of atherosclerotic diseases. Apolipoprotein C-III (apoC-III) gene variants, which vary by race/ethnicity, have been associated with a lipid profile that resembles PI-induced dyslipidemia. However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported.
###end p 6
###begin title 7
Methods and Findings
###end title 7
###begin p 8
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
A cross-sectional analysis of race/ethnicity, apoC-III/apoA-I genotypes, and PI exposure on plasma lipids was performed in AIDS Clinical Trial Group studies (n = 626). Race/ethnicity was a highly significant predictor of plasma lipids in fully adjusted models. Furthermore, in stratified analyses, the effect of PI exposure appeared to differ across race/ethnicity. Black/non-Hispanic, compared with White/non-Hispanics and Hispanics, had lower plasma triglyceride (TG) levels overall, but the greatest increase in TG levels when exposed to PIs. In Hispanics, current PI antiretroviral therapy (ART) exposure was associated with a significantly smaller increase in TGs among patients with variant alleles at apoC-III-482, -455, and Intron 1, or at a composite apoC-III genotype, compared with patients with the wild-type genotypes.
###end p 8
###begin title 9
Conclusions
###end title 9
###begin p 10
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 293 298 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia. Given the multi-ethnic distribution of HIV-1 infection, our findings underscore the need for future studies of metabolic and cardiovascular complications of ART that specifically account for racial/ethnic heterogeneity, particularly when assessing candidate gene effects.
###end p 10
###begin p 11
This cross-sectional analysis of race/ethnicity, apoC-III/apoA-I genotypes, and protease inhibitor exposure on plasma lipids showed that race/ethnicity was a highly significant predictor of plasma lipids
###end p 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b001">1</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b003">3</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b004">4</xref>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b005">5</xref>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b002">2</xref>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b003">3</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b006">6</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b007">7</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b004">4</xref>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b008">8</xref>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b009">9</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 256 259 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 883 888 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 996 1001 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The use of potent antiretroviral therapy (ART) in patients with HIV-1 is associated with a cluster of metabolic complications, including atherogenic dyslipidemia [1-3]. Analyses of data in 17,852 patients from the Data Collection on Adverse Events of Anti-HIV Drugs study document class effects of ART on lipid profiles, with dyslipidemias observed most commonly in patients receiving protease inhibitors (PIs) [4,5]. Lipid abnormalities on PIs are characterized by elevated triglycerides (TGs), low high-density lipoprotein cholesterol (HDL-c) and increased apolipoprotein (apo) B, containing very low-density lipoprotein remnants and small low-density lipoprotein particles [2,3,6,7]. Recent studies suggest that PI-based ART is associated with an increased risk for atherosclerotic cardiovascular (CV) events [4,8,9] and has raised concerns for a future epidemic of CV disease in HIV-1 patients for whom life-long ART may be required for control of viral replication. Strategies that identify HIV-1 individuals at increased risk of ART-related metabolic complications are likely to facilitate rational decision making when selecting ART regimens, as well as early use of appropriate preventive CV therapies in those at greatest risk.
###end p 13
###begin p 14
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b002">2</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b010">10</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b011">11</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b012">12</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b013">13</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b005">5</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b016">16</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b017">17</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b019">19</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b002">2</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b010">10</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b020">20</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b021">21</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b022">22</xref>
###xml 51 54 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 554 559 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The pathophysiology of dyslipidemia in ART-treated HIV patients is multi-factorial and involves drug effects on lipid metabolism [2,10], insulin signaling and adipose tissue [11], immunologic or viral factors [12], and host genetics [13-15]. Lipid abnormalities have been associated with almost all PIs, but vary with specific PIs, and are most frequent in patients taking ritonavir (RTV) or RTV-"boosted" PI combination regimens [5,16]. The direct effect of PIs on lipid metabolism is evident by elevations in TG following short courses of treatment in HIV-1-uninfected, healthy individuals [17-19]. PIs modulate both the production of apoB particles and their clearance [2,10,20]. Notably, PI ART-related dyslipidemia resembles that observed in familial combined hyperlipidemia [21], suggesting a potential role for variation in lipoprotein genes that have been linked to this relatively common inherited dyslipidemia [22].
###end p 14
###begin p 15
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b023">23</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b024">24</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b025">25</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b026">26</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b027">27</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b024">24</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b028">28</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b030">30</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b013">13</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 620 625 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
ApoC-III is a 79-amino-acid protein whose plasma levels are directly correlated with TGs in the general population [23]. Although the in vivo function of apoC-III is poorly understood [24], in vitro studies and gene manipulation in mouse models have implicated apoC-III in regulating lipolysis of TG-rich lipoprotein [25], and in modulating remnant particle clearance by the liver [26,27]. Several studies have established a complex interaction of genetic variation within apoC-III, and the apoA-I/C-III/A-IV/AV cluster, with plasma TG levels [24,28-30]. Recently, two groups reported a marked increase in plasma TGs in HIV-1-infected patients on PI ART regimens when they also carried a combination of apoC-III and apoE gene variants [13,15], although these studies were restricted almost entirely to Caucasians.
###end p 15
###begin p 16
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b031">31</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b033">33</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b034">34</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b036">36</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b036">36</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b028">28</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b030">30</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b039">39</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b040">40</xref>
###xml 207 212 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 351 356 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 829 834 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Despite a well-described relationship of race/ethnicity with lipoproteins in the general population [31-33], there has been little consideration of ethnicity in the development of metabolic complications in HIV-1-infected individuals. Such differences may be of specific relevance in ART-associated dyslipidemia given the multi-ethnic distribution of HIV-1 infection and evidence for ethnic differences in linkage disequilibrium (LD) patterns for several lipoprotein genes [34-36]. We hypothesized that ethnic LD patterns in apoC-III [36-38], as well as distinct susceptibility/resistance alleles for lipid abnormalities [28-30,39], and prior evidence for modification of apoC-III effects by ethnicity [38,40], would result in differences across racial/ethnic stratum in the association of apoC-III and ART with plasma lipids in HIV-1 infection.
###end p 16
###begin p 17
###xml 116 121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We describe results of analyses from an ongoing project designed to identify candidate genes that place ART-treated HIV-1-infected individuals at higher risk of developing dyslipidemia. As a primary hypothesis, we aimed to determine whether race/ethnicity is a significant predictor of plasma lipids and ART-associated lipid abnormalities in HIV-1-infected individuals and whether apoC-III/apoA-I gene variants interacted with PI exposure to predict increased plasma TGs within race/ethnicity strata.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
###xml 6 18 <span type="species:ncbi:9606">Participants</span>
Study Participants
###end title 19
###begin p 20
###xml 958 960 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b041">41</xref>
###xml 1257 1258 1257 1258 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 93 96 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 97 109 <span type="species:ncbi:9606">participants</span>
###xml 444 456 <span type="species:ncbi:9606">participants</span>
###xml 480 492 <span type="species:ncbi:9606">participants</span>
###xml 664 676 <span type="species:ncbi:9606">participants</span>
###xml 1068 1071 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1164 1176 <span type="species:ncbi:9606">participants</span>
###xml 1488 1496 <span type="species:ncbi:9606">patients</span>
###xml 1511 1514 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1654 1662 <span type="species:ncbi:9606">patients</span>
###xml 1747 1755 <span type="species:ncbi:9606">patients</span>
###xml 1866 1869 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
As part of New Work Concept Sheet (NWCS) 224, we performed a cross-sectional analysis of 626 HIV participants enrolled in selected AIDS Clinical Trial Group (ACTG) studies (28% from A5005s, 11% from A5068, 18% from A5087, 19% from ACTG 372, and 23% from A5116) who also had consented to collection and storage of their blood for genetic studies (A5128). ACTG studies were approved by local institutional review boards at each institution where participants were recruited and all participants gave written informed consent. These specific ACTG studies were selected because appropriate data, including fasting plasma lipids and DNA samples, were available and all participants were on ART at time of sampling. Study A5005s was the metabolic sub-study of ACTG 384, a six-arm comparison of three- or four-drug ARTs with zidovudine and lamivudine, or stavudine and didanosine, combined with efavirenz (EFV), nelfinavir (NFV), or both, in ART-naive individuals [41]. ACTG 5068 compared two strategies, treatment interruption and vaccination with ALVAC vCP1452, to augment HIV-specific immune responses in individuals on stable ART. Protocol A5087 enrolled ART-treated participants with dyslipidemia who were randomized to one of two lipid-lowering interventions. ACTG 372 was a rollover study for ACTG 320 to compare individuals receiving abacavir or a placebo in combination with zidovudine, lamivudine, and indinavir. Finally, A5116 was a class-sparing and regimen-simplification study for patients with advanced HIV disease. A more detailed description of the above mentioned studies can be found at . In our analysis, fasting lipids were recorded in all patients in A5087 prior to starting lipid-lowering therapy. Fasting lipids were recorded for patients in A5005 at least 32 wk after start of ART, and for all other studies at entry. Because lipid levels prior to HIV therapy were not consistently available, our study represents an analysis of treatment lipids across these ACTG studies.
###end p 20
###begin p 21
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 12 24 <span type="species:ncbi:9606">participants</span>
###xml 246 254 <span type="species:ncbi:9606">Patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
Among study participants, n = 440 were on stable PI ART (n = 398 on a non-RTV regimen) (and n = 42 on a RTV regimen; median exposure 976 d; interquartile ranges [IQR] = 244, 1245) or non-PI ART (n = 131; 78% EFV and 13% NFV-containing regimens). Patients with short exposure to PI ART (<90 d; n = 13), patients not currently on PIs but who were exposed to a PI within 30 d (n = 2), and patients with unknown durations of exposure (n = 40) were excluded from analysis assessing PI effects.
###end p 21
###begin title 22
Evaluated Parameters
###end title 22
###begin p 23
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants were evaluated through their respective ACTG protocols. Demographic and clinical information was provided to the NWCS224 team in a blinded, de-linked manner from the Statistical and Data Analysis Center of the Center for Biostatistics and AIDS Research at the Harvard School of Public Health. Race/ethnicity data were self-reported in these ACTG studies with race categorized as Black, Caucasian, American Indian, Alaska Native, Native Hawaiian, other Pacific Islander, or Asian; and ethnicity as Hispanic or non-Hispanic. For the purpose of our analysis, a single three-level race/ethnicity variable was defined, which represented 97.6% of the full sample: White/non-Hispanic (White), Black/non-Hispanic (Black), or Hispanic. Clinical information collected included medical histories, concomitant medications, ART history, CD4 counts, viral loads, height, weight, fasting plasma lipoproteins (TG, HDL-c, total cholesterol), and glucose. Fasting plasma lipids were measured according to the specific parent ACTG protocols. Non-HDL-c was calculated by subtracting HDL-c from total cholesterol. For the measured lipid data, >97% was confirmed to have been taken in the fasting state, the other <3% were presumed to be fasting based on study specific criteria. Body mass index was calculated as weight divided by height squared.
###end p 23
###begin title 24
Genotyping
###end title 24
###begin p 25
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b024">24</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b028">28</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b030">30</xref>
DNA samples were isolated from blood (PUREGENE blood kits; Gentra Systems, Minneapolis, Minnesota, United States) at the ACTG DNA core laboratory at Vanderbilt University, Nashville, Tennessee, United States. We genotyped six single nucleotide polymorphisms (SNPs) in the apoC-III/apoA-I cluster, five in apoC-III (-482C/T [rs2854117], -455T/C [rs2854116], intron 1 (466)G/C [rs2070669], Gly34Gly C/T [rs4520], and exon 4 SstI 3238(5)C/G [rs5128]), and one in apoA-I (XmnI; -2500C/T; chromosome position 11626561, May 2004 assembly []). SNPs were chosen based on prior knowledge of association with plasma lipoproteins (apoC-III-482C/T, -455T/C, SstI 3238C/G, and apoA-I-2500C/T) [24,28-30] and to provide additional information of LD across apoC-III in these analyses (intron 1 G/C and Gly34Gly in apoC-III). Genotyping was performed at Penn Genotyping Core employing Taqman (Applied Biosystems, Foster City, California, United States) ABI SNP genotyping assays were performed using the ABI 7900HT.
###end p 25
###begin title 26
Statistical Analysis
###end title 26
###begin p 27
Analyses were performed using Splus for Windows, Version 6.2 and R, version 2.0. Demographic and clinical characteristics are given overall and by specific ACTG study. Data are reported as medians and IQR for continuous variables, and as proportions for categorical variables. Raw lipoprotein data are presented by race/ethnicity, gender, and drug exposures. Log transformations were employed to normalize lipoprotein data for the purpose of modeling.
###end p 27
###begin p 28
As a first step, we assessed the main effects of race/ethnicity and PI exposure on plasma lipids, using multiple linear regression modeling. As a primary analysis, models were fitted treating PI exposure as a three-level factor (no current PI exposure, currently exposed to a non-RTV-containing PI regimen, and currently exposed to a RTV-containing regimen). An analysis of PI exposure as an indicator for any current PI use was also performed. Fully adjusted multivariable models included race/ethnicity, ART exposures (current use of PI, stavudine, EFV, and NFV), age, gender, study, CD4 count, and use of lipid-lowering therapy. Maximum likelihood coefficient estimates (reported as estimated fold increases in each lipid outcome on the un-logged scale), 95% confidence intervals (CI) for the true effects, and F-test statistics are reported. In addition, separate multivariable models were fitted for each SNP to assess their independent main effects on lipid outcomes. SNPs were coded as binary indicators for the presence of at least one variant allele (i.e., heterozygous or homozygous rare.) Although useful for comparison with published studies, a notable limitation of this first step is that it does not account for potential interaction between race/ethnicity, PI exposure, and genotypes.
###end p 28
###begin p 29
We performed all subsequent analyses stratified by race/ethnicity in order to address our primary hypothesis of an interaction between genotype and PI exposure on TGs within racial/ethnic stratum. Maximum likelihood estimates and 95% CIs for main effects of PI exposure and interaction effects between PI exposure and apoC-III/apoA-I SNPs were estimated within race/ethnicity stratum, based on fully adjusted multivariable linear regression models. In these models, PI exposure was treated as a two-level indicator for any current exposure because there is no mechanistic data to support differential interaction effects of apoC-III genotypes with distinct PIs. Estimated fold increases in TGs and corresponding 95% CIs on the un-logged scale are again reported and significance is based on a two-sided Wald test at the 0.05 level. Predicted TG levels and 95% CIs, based on these fully adjusted multivariable models, are provided for non-PI and PI groups within racial/ethnic stratum, with and without further stratification by genotype.
###end p 29
###begin p 30
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
Due to the high degree of concordance among the observed apoC-III SNPs, an additional composite genotype analysis is presented. As a primary analysis, the three apoC-III SNPs described by Tarr et al. (-482, -455, and SstI [3238]) [15] were considered, and a new binary variable for the presence of one or more variant allele at any number of these three SNPs was created. The interaction between this composite genotype variable and PI exposure was assessed within racial/ethnic stratum as described above for the single SNP PI interaction. Although power for three-way interactions was limited, the interaction of individual SNPs and the composite genotype, with race/ethnicity and PI exposure was estimated and tested for completeness.
###end p 30
###begin p 31
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b042">42</xref>
Estimation of apoC-III haplotype frequencies within race/ethnic strata and the assessment of whether these haplotypes modified the effects of PI exposure on TGs, was performed using the R functions haplo.em and haplo.glm in the haplo.stats library as described by Lake et al. [42]. This approach allows for estimating and testing interaction effects between haplotypes and PI exposure when linkage phase is ambiguous and employs an expectation-maximization type algorithm that iterates between estimating haplotype probabilities and estimating regression parameters.
###end p 31
###begin title 32
Sample Size Considerations
###end title 32
###begin p 33
The sample size provides greater than 80% power to detect moderate PI genotype interaction effect sizes of 0.23, 0.36, and 0.35 within Whites, Blacks, and Hispanics, respectively, using a two-sided level = 0.05 test, and within-cell respective assumed standard deviations of 0.7, 0.5, and 0.6 based on observed data (NCSS 2001 PASS 2000.) Notably, our analysis is not able to rule out smaller underlying interaction effects.
###end p 33
###begin title 34
Results
###end title 34
###begin p 35
###xml 62 70 62 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st001">Table S1</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b043">43</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 294 306 <span type="species:ncbi:9606">participants</span>
###xml 392 395 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 539 542 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Demographic and clinical information by study are provided in Table S1. Median age of the cohort was 41 (IQR: 36 to 48), 89% were male, and 39 patients were on lipid-lowering therapies. Median CD4 was 442 (IQR: 294.3 to 642.8) and 91.1% of patients had RNA copies <400. The proportion of Black participants (19.3%) was somewhat lower than that enrolled in all ACTG studies (27%) or receiving HIV care (33%) [43], but overall gender, race, and age distributions in our study sample were consistent with population estimates for ART-treated HIV adults in the United States. As expected from ACTG study-specific criteria, a number of characteristics, including type of ART, race/ethnicity, use of lipid-lowering therapy, and lipid levels, differed across studies, underscoring the need to control for potential confounding by study.
###end p 35
###begin p 36
###xml 74 81 74 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t001">Table 1</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b005">5</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 89 101 <span type="species:ncbi:9606">participants</span>
###xml 198 210 <span type="species:ncbi:9606">participants</span>
###xml 396 408 <span type="species:ncbi:9606">participants</span>
Summaries of lipid outcomes by race/ethnicity and gender are presented in Table 1. Black participants tended to have lower TGs and non-HDL-c and higher HDL-c than Whites and Hispanics. As expected, participants on any number of PIs (compared to those not on PIs) tended to have higher TGs and non-HDL-c. Consistent with previous reports [5,15], the most abnormal lipid profiles were observed for participants on RTV-containing PI regimens.
###end p 36
###begin title 37
Association of Race/Ethnicity, PI Exposure, and ApoC-III/ApoA-I Genotypes with Plasma Lipids
###end title 37
###begin p 38
###xml 193 200 193 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t002">Table 2</xref>
###xml 700 708 700 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st002">Table S2</xref>
###xml 386 398 <span type="species:ncbi:9606">participants</span>
###xml 536 548 <span type="species:ncbi:9606">participants</span>
Race/ethnicity was a highly statistically significant predictor of plasma lipids even after controlling for gender, study, age, CD4 count, use of lipid-lowering therapy, and ART drug exposure (Table 2). Overall, Blacks had lower TG and non-HDL-c and higher HDL-c than Whites and Hispanics in fully adjusted models. PI exposure was also a significant predictor of TGs and non-HDL-c with participants receiving RTV-containing PI therapy having an estimated 1.46-fold greater TG levels and 1.25-fold greater non-HDL-c levels compared with participants receiving non-PI therapies. There were no significant associations between individual apoC-III/apoA-I SNPs and plasma lipids in fully adjusted models (Table S2.) Overall, these analyses are limited due to potential for differential PI effects on lipids across racial/ethnicity and the modifying effects of apoC-III/apoA-I genotypes on PI association with lipids.
###end p 38
###begin title 39
Modification of PI Effects on Plasma TG by Race/Ethnicity
###end title 39
###begin p 40
###xml 18 26 18 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030052-g001">Figure 1</xref>
###xml 26 27 26 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
###xml 762 774 <span type="species:ncbi:9606">participants</span>
As illustrated in Figure 1, current exposure to non-RTV- and RTV-containing PI regimens (compared to no current PI exposure), without consideration for genotypes, tended to be associated with higher TGs, and the strength of this association varied across race/ethnicity. Of note, non-RTV-containing PI regimens were associated with increased plasma TGs in Black/non-Hispanics (estimated fold increase = 1.39, 95% CI = [1.02, 1.89]). This trend was also observed in Hispanics (estimated fold increase = 1.23, 95% CI = [0.89, 1.69]), but not in Whites (estimated fold decrease = 0.97, 95% CI = [0.80, 1.18]). RTV-containing PI therapy appears to be associated with even greater increases in TGs within all racial/ethnic groups, though the within-strata numbers of participants on RTV are small.
###end p 40
###begin title 41
Modification of PI Effects on Plasma TG by ApoC-III/ApoA-I Genotypes within Race/Ethnic Strata
###end title 41
###begin p 42
###xml 60 68 60 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="st003">Table S3</xref>
###xml 494 501 494 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t003">Table 3</xref>
Genotype frequencies varied markedly across race/ethnicity (Table S3). For example, 53.4% of Whites had the apoC-III-482CC genotype, while only 8.3% of Blacks and 35.7% of Hispanics had this genotype. Similar race/ethnicity-specific differences were seen for apoC-III, -455, and apoC-III Intron 1. After stratifying by race/ethnicity, tests of departures from Hardy-Weinberg Equilibrium were not significant for any of the SNPs (unpublished data). The estimated haplotype frequencies (given in Table 3) varied similarly across race/ethnicity with the "wild-type" haplotye (-482C, -455T, Intron 1G, Gly34GlyC, 3238C) frequency estimated at 45.5% in Whites, 10.8% in Blacks, and 35.1% in Hispanics.
###end p 42
###begin p 43
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t004">Table 4</xref>
###xml 625 632 625 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t005">Table 5</xref>
###xml 309 321 <span type="species:ncbi:9606">participants</span>
###xml 437 449 <span type="species:ncbi:9606">participants</span>
Table 4 illustrates the interactions between PI exposure and each of the six SNPs in apoC-III/apoA-I on TG levels within race/ethnicity strata. The effect of PI exposure on TG levels varied by apoC-III-482, -455, and intron 1 genotypes in Hispanics. As an illustration, the effect of PI exposure for Hispanic participants with no variant alleles at apoC-II-482 was to increase TGs 1.79-fold, while the effect of PI exposure for Hispanic participants with one or more variant alleles at apoC-III-482 was to decrease TGs 0.97-fold ( = 1.79 x 0.54). Predicted TG levels by race/ethnicity, PI exposure, and genotype are given in Table 5 and provide an illustration of these interaction effects.
###end p 43
###begin p 44
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0030052-t005">Table 5</xref>
###xml 1019 1020 1019 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1044 1045 1044 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1074 1075 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1113 1114 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 399 411 <span type="species:ncbi:9606">participants</span>
###xml 458 470 <span type="species:ncbi:9606">participants</span>
A significant difference in the effect of PI exposure on TGs across genotypes in Whites and in Blacks was not detectable. However, predicted TG levels across genotypes did differ across the three ethnic groups (Table 5), suggesting race-specific differences in the influence of apoC-III genotypes on PI-related dyslipidemia. The difference in predicted TGs between PI-exposed and unexposed Hispanic participants with the apoC-III-482 CC genotype compared to participants with the CT/TT genotype (+ 0.8 mmol/l versus -0.1 mmol/l) appears to be different from that in Whites (-0.1 mmol/l versus + 0.3 mmol/l) and Blacks (-0.4 mmol/l versus + 0.3 mmol/l). Thus, in contrast to Hispanics, PI exposure tended to be associated with higher TGs in Whites and Blacks with the -482 CT/TT genotypes, but not in those with the CC genotype. In fully adjusted models that combined racial/ethnic groups, the three-way interaction effects between PI use, SNPs, and Hispanic race/ethnicity were marginally significant for apoC-III-482 (p = 0.07), apoC-III-455 (p = 0.08), apoC-III Intron 1 (p = 0.03), and apoA-I XmnI (-2500T/C) (p = 0.06).
###end p 44
###begin title 45
Modification of PI Effects on Plasma TG by Composite ApoC-III Genotypes within Race/Ethnic Strata
###end title 45
###begin p 46
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 312 313 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
The tests of interaction between each SNP and PI exposure are not independent due to the high degree of concordance across genotypes: n = 96 out of 104 (92.3%) Hispanics were concordant in their genotypes for -482 and -455 (i.e., they were wild-type for both or variant for both based on the binary SNP coding); n = 99 of 104 (95.2%) were concordant for -482 and Intron 1; and n = 92 of 104 (88.5%) were concordant for all three SNPs.
###end p 46
###begin p 47
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 493 494 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 671 672 671 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 738 746 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030052-g002">Figure 2</xref>
###xml 296 308 <span type="species:ncbi:9606">participants</span>
###xml 526 538 <span type="species:ncbi:9606">participants</span>
###xml 657 669 <span type="species:ncbi:9606">participants</span>
Consistent with the single SNP analysis, there appears to be a protective effect of the composite variant genotype, (apoC-III -384, -355, and SstI [3238]) on the association of PIs with TG levels within Hispanics (interaction effect = 0.56, 95% CI = [0.32, 0.97], p-value = 0.04). Among Hispanic participants with no variant alleles at the three apoC-III SNPs indicated (n = 72), PI exposure (n = 57) was associated with 1.89-fold higher plasma TG levels compared to the non-PI-exposed group (n = 15); however, among Hispanic participants with a variant allele at one or more of the three apoC-III SNPs indicated (n = 32), the increase in TGs in PI-exposed participants (n = 23) versus non-PI-exposed subjects (n = 9) was only 1.06-fold (Figure 2). Similar to the single SNP analysis, the three-way interaction between PI use, genotype, and race/ethnicity was marginally significant (0.055) with an estimated fold decrease of 0.52. Analyses did not reveal significant haplotype PI-interaction effects on TGs. However, within Hispanics, the interaction effects of the non-wild-type haplotypes with PI exposure were 0.84- and 0.75-fold decreases for additive or dominant models respectively, which is consistent with the direction and magnitude of effects observed for composite genotypes and individual SNP analyses.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b031">31</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b033">33</xref>
###xml 132 137 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 222 227 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 407 412 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 506 511 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
###xml 991 999 <span type="species:ncbi:9606">patients</span>
Our study is the first of race/ethnicity influences on plasma lipoproteins and is the largest study of genetic effects on lipids in HIV-1-infected patients. We found that race/ethnicity was a predictor of plasma lipids in HIV-1 patients on ART. Overall, Black patients on ART had a less atherogenic lipid profile compared to Whites and Hispanics. This finding is consistent with epidemiological data in non-HIV-1 populations [31-33], but may be of particular importance given the worldwide demographics of HIV-1 infection. Despite lower plasma lipids, the effect of PI exposure on TGs was most marked in Blacks, and, in fact, the effect of non-RTV PI therapy appeared to be stronger in both Blacks and Hispanics compared to Whites. We also found a significant difference in the influence of apoC-III genotypes and PI use across ethnic groups in the association with TGs. Hispanic patients with individual apoC-III variant alleles, or across a composite apoC-III genotype, had lower TGs than patients with the wild-type genotypes when on PI therapy. This interaction was not observed in Whites and Blacks. Overall, these results provide evidence for race-specific differences in both the occurrence of dyslipidemia on ART as well as in the influence of genetic factors on the prevalence of PI-related lipid abnormalities.
###end p 49
###begin p 50
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b023">23</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b028">28</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b029">29</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b039">39</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b044">44</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b045">45</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b024">24</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b046">46</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b047">47</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b046">46</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b048">48</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b029">29</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b030">30</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b049">49</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b050">50</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b039">39</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b045">45</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b036">36</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b051">51</xref>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b054">54</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b040">40</xref>
###xml 1212 1213 1212 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1242 1244 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
Linkage and association studies have established a relationship of apoC-III genotypes, and the apoA-I/CIII/AIV/AV gene cluster, with alterations in plasma TGs [23,28,29,39,44,45]. However, little is known of the molecular mechanisms [24]. The concurrence of SNPs in these linked genes complicates the assignment of metabolic effects to individual variants. For example, most [46,47] evidence suggest that two apoC-III promoter SNPs (-482C/T and -455T/C) attenuate the inhibitory action of insulin on apoC-III gene expression and influence plasma lipids [46,48]. However, almost all studies suggest that these SNPs are associated with lipid levels through their LD with the well studied 3' UTR SstI (3238) variant [29,30,49,50], which may, in turn, be associated with TG levels through LD with variants elsewhere in the cluster [39,45]. In fact, apoA-I/CIII/AIV/AV SNP and haplotype frequencies vary markedly across ethnic groups [36-38], but most studies of the gene cluster have been restricted to Whites. Furthermore, several environmental factors [51-54], including race/ethnicity [38,40], appear to modify the impact of apoC-III variation on lipids and metabolic traits. For example, in a tri-ethnic sample (n = 1,366) Waterworth et al. [38] found an association of the -482T allele with increases in metabolic parameters in Whites, but decreases in these readouts in African-ancestry individuals.
###end p 50
###begin p 51
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b013">13</xref>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 126 131 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 236 241 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 559 564 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
Recent work has demonstrated a potential interaction of lipoprotein genes with PI therapy in promoting lipid abnormalities in HIV-1-infected patients. Fauvel et al. studied 60 consecutive, PI-treated (mostly indinavir) White males with HIV-1, who were also taking two nucleoside reverse transcriptase inhibitors, and found that the rare apoC-III -455C, -482T, or SstI-S2(G) variants were associated with higher TGs and apoB lipoproteins as well as lower HDL-c [13]. Tarr et al. assessed the effect of apoE and apoC-III genotypes on change in lipids on ART in HIV-1-infected patients (n = 329) [15]. They found that those patients on RTV, who also had apoE variants (non 3/3) and all three -482T, -455C, and 3238G (SstI) apoC-III polymorphisms, had marked increases in TG levels.
###end p 51
###begin p 52
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 195 200 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
Both of these studies, predominantly of Whites, concluded that the apoC-III-482 (CT and TT), -455 (TC and CC), and 3238 (SstI) (GC and GG) genotypes may be associated with increased TG levels in HIV-1-infected patients on PIs. We did not detect significant interaction effects of these apoC-III genotypes with PIs on plasma TGs in Whites. Despite this, our findings are broadly consistent with these papers in that TG levels in White and Blacks with these genotypes on PIs in our study tended to be higher than individuals not on PI therapy; however, the magnitude of effects on lipids were more modest. These differences may reflect study design and confounding variables including age, gender, concurrent use and type of non-PI ART, the prevalence of diabetes, and use of lipid-lowering medications. Furthermore, we did not consider apoE or other candidate genes that might further modify the association of PIs with dyslipidemia. Notably, in Tarr et al. the interaction with PI therapy was only significant in those individuals with the combination of apoE and apoC-III variants [15].
###end p 52
###begin p 53
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b055">55</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b036">36</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b028">28</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b029">29</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b039">39</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b045">45</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b050">50</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b038">38</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b040">40</xref>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b013">13</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 1309 1314 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As hypothesized, we found evidence of race/ethnic differences in the association of apoC-III genotypes with PI-related dyslipidemia as well as marked race/ethnicity specific differences in SNP and estimated haplotype frequencies. Although our findings of a potential protective effect of the non-wild-type apoC-III variants on PI-induced hypertriglyceridemia in Hispanics is not consistent with studies in White samples, they are not surprising in the context of prior studies that demonstrated complex transcriptional regulation of the apoA-I/CIII/AIV/AV gene cluster [55], race/ethnic specific LD across this region [36-38], interplay of distinct alleles that confer susceptibility/resistance to hypertriglyceridemia [28,29,39,45,50], and prior evidence for modification of apoC-III effects by race/ethnicity [38,40]. Our finding does not imply that "race" is responsible for specific differences in SNP functional effects. Rather, it is much more likely that differences relate to race/ethnicity-specific LD with unmeasured functional variants in the apoA-I/C-III/AIV/AV cluster, or to the confounding influence of additional environmental or genetic factors which also vary with race/ethnicity. For these reasons, we believe that our findings are not in conflict with published studies including those in HIV-1 samples [13,15].
###end p 53
###begin p 54
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b034">34</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b056">56</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b034">34</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b056">56</xref>
###xml 1055 1057 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b057">57</xref>
Race/ethnicity is often considered a surrogate for environmental influences on lipids, but recent studies demonstrate that genetic factors also account for important differences in plasma lipids across ethnic groups [34,56]. For example, hepatic lipase SNPs, present only in African Americans, result in lower enzyme activity and account for a significant proportion of the race/ethnic differences in HDL-c levels [34]. Recently, Cohen et al. reported that loss-of-function mutations in proprotein convertase subtilisin kexin-9, a gene that regulates hepatic low density lipoprotein receptor expression, were associated with markedly lower plasma levels of low density lipoprotein and that these mutations were relatively common in African Americans but rare in European Americans [56]. In this context, it is likely that genetic variation, as well as environmental factors, contribute to significant region-specific differences in lipid and metabolic complications of ART, such as those noted in the recently completed 2NN multi-national clinical trial [57].
###end p 54
###begin p 55
###xml 331 332 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b013">13</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b015">15</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b058">58</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b059">59</xref>
###xml 1210 1215 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1270 1278 <span type="species:ncbi:9606">patients</span>
The main limitation of our study is that it was cross-sectional, involved a heterogeneous, multi-ethnic sample across ACTG studies, and had limited power to detect small interaction effects within race/ethnic strata. Our goal was to characterize trends in the data, and we caution against placing too much emphasis on the absolute p-values, since type I errors due to multiple testing are possible with subgroup analyses. Due to the highly correlated nature of many of the reported tests, induced by the overlap in genotypes across SNPs, we included an analysis of a single composite genotype variable that is consistent with multi-locus analysis approaches in the literature [13,15,58,59]. While this approach is not a correction for multiple testing, it lends strong support to the single SNP analysis and is an appropriate alternative for our setting. Our findings require further evaluation, ideally in large prospective cohort or randomized trial settings that determine changes in lipids over time and also allow a careful assessment of additional environmental (e.g., diet and smoking) and genetic factors (e.g., apoE and lipase genotypes). However, to date this is the largest pharmacogenetic study in HIV-1 to address ethnic variation in plasma lipoproteins in patients on ART.
###end p 55
###begin p 56
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b060">60</xref>
###xml 756 761 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Overall, our findings of race/ethnicity-specific apoC-III-PI interaction on plasma TGs should be interpreted cautiously. Based on an examination of 43 meta-analyses of genetic association studies, Ioannidis et al. concluded that the biological impact of genetic markers on risk for common diseases is usually consistent across racial boundaries [60]. However, they did find almost a 3-fold greater occurrence of race-specific heterogeneity in genetic effects than would be expected by chance. Thus, the challenge lies in identifying which genetic effects may be influenced by race/ethnicity and what is the basis of such influences. Our findings caution against generalizing results of genetic studies in White samples when considering metabolic traits in HIV-1 populations, particularly for genes with known complex LD structures reported to vary by race/ethnicity.
###end p 56
###begin p 57
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b016">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030052-b061">61</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 319 324 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In summary, this study provides novel information regarding HIV-1 subgroups that may be at differential risk of developing metabolic and CV complications of ART. Approaches that account for racial/ethnic heterogeneity are mandated in pharamcogenetic studies of such complications given the multi-ethnic distribution of HIV-1 infection, concerns regarding future atherosclerotic CV disease in these populations, and the potential to use alternative strategies [16,61] to reverse or avoid metabolic effects of ART.
###end p 57
###begin title 58
Supporting Information
###end title 58
###begin title 59
Demographic and Clinical Characteristics by Study
###end title 59
###begin p 60
(134 KB DOC).
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin title 62
Individual SNP Effects on Lipids in Multivariable Adjusted Models with Racial/Ethnic Groups Combined
###end title 62
###begin p 63
(37 KB DOC).
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin title 65
Genotype Frequencies by Race/Ethnicity
###end title 65
###begin p 66
(46 KB DOC).
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin title 68
Accession Numbers
###end title 68
###begin p 69
The EntrezGene (prior LocusLink) accession numbers for genes/proteins referred to in this paper are apoA-I (335), apoA-IV (337), apoA-V (116519), apoC-III (345), and apoE (348).
###end p 69
###begin title 70
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Summary
###end title 70
###begin title 71
Background
###end title 71
###begin p 72
###xml 102 105 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 505 510 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
One of the unfortunate side effects of protease inhibitors-one of the types of drugs used in treating HIV-is that they affect lipids in the body; for example, they cause the level of triglycerides to increase in such a way as to make it more likely that patients will develop diseases associated with abnormal lipids such as heart disease and stroke. As these drugs are taken for very long periods of time, there are concerns that there may be a future epidemic of cardiovascular disease in patients with HIV-1 who have taken such lifelong treatment.
###end p 72
###begin title 73
Why Was This Study Done?
###end title 73
###begin p 74
###xml 66 69 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The authors wanted to see if they could identify individuals with HIV who are at increased risk of getting the lipid abnormalities caused by these drugs; in particular, they wanted to see if there were differences across different racial/ethnic groups and according to common variation in some lipid genes. Knowing about such differences might help in deciding between the various different drug treatments available.
###end p 74
###begin title 75
What Did the Researchers Do and Find?
###end title 75
###begin p 76
###xml 19 25 <span type="species:ncbi:9606">people</span>
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
They looked at 626 people who had taken part in previous studies of HIV drugs, and who had agreed to have their blood stored for further studies such as these. They found that race/ethnicity could help predict levels of plasma lipids, and that the effect of taking protease inhibitors also appeared to differ across race/ethnicity groups. Overall, Black patients taking these drugs were less likely to have the lipid profiles that lead to cardiovascular disease, compared to Whites and Hispanics. However, individuals in all racial/ethnic groups had increases in triglyceride levels when they were given these drugs. Furthermore, Hispanics, but not Whites or Blacks, with variation in the apoC-III gene, appeared to be protected from the triglyceride-raising effect of protease inhibitors
###end p 76
###begin title 77
What Do These Findings Mean?
###end title 77
###begin p 78
###xml 11 14 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 263 266 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
Given that HIV is a disease that affects all racial/ethnic groups, it will be important in the future to study carefully and in large numbers the patients of all racial/ethnic groups in studies of metabolic and cardiovascular complications of drugs used to treat HIV. It may also be necessary to look at the effect of certain genes on these lipids. In the future it may be possible to use this information to decide which patients should receive which drugs.
###end p 78
###begin title 79
Where Can I Get More Information Online?
###end title 79
###begin p 80
###xml 108 111 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 164 167 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
AIDSinfo is a site run by the National Institutes of Health in the US that has many pages of information on HIV. Searching for "lipid" will bring up fact sheets on HIV drugs and the type of lipid changes discussed in this article:
###end p 80
###begin p 81

###end p 81
###begin p 82
###xml 18 21 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TheBody.com is an HIV/AIDS resource that can be searched for information on the effects of these drugs on lipids. One page to start at is:
###end p 82
###begin p 83

###end p 83
###begin p 84
Special thanks to Robert A. Parker in the Statistical and Data Management Center of the AIDS Clinical Trials Group (ACTG) for valuable input. Support for this research was provided by National Institute of Allergy and Infectious Diseases (NIAID: R01 AI056983), a Center for AIDS Research (CFAR) Development Award from the University of Pennsylvania (5-P30 AI45008), a New Works Concept Sheet (NWCS 224) award from the ACTG, the University of Pennsylvania AIDS Clinical Trial Unit (ACTU: AI32783), the University of North Carolina CFAR (AI50410-04) and ACTU (5 U01 AI25868-17), the Indiana University ACTU (AI25859) and GCRC (RR-00750), and the Adult ACTG funded by the NIAID (AI38858).
###end p 84
###begin p 85
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 85
###begin title 86
References
###end title 86
###begin article-title 87
###xml 28 31 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 97 100 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study
###end article-title 87
###begin article-title 88
###xml 11 14 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Effects of HIV protease inhibitor therapy on lipid metabolism
###end article-title 88
###begin article-title 89
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cardiovascular risk and body-fat abnormalities in HIV-infected adults
###end article-title 89
###begin article-title 90
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study
###end article-title 90
###begin article-title 91
###xml 18 21 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?
###end article-title 91
###begin article-title 92
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection
###end article-title 92
###begin article-title 93
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy
###end article-title 93
###begin article-title 94
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 58 <span type="species:ncbi:9606">persons</span>
Cardio- and cerebrovascular events in HIV-infected persons
###end article-title 94
###begin article-title 95
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 100 103 <span type="species:ncbi:9606">men</span>
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
###end article-title 95
###begin article-title 96
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
###end article-title 96
###begin article-title 97
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 59 62 <span type="species:ncbi:9606">men</span>
Metabolic effects of indinavir in healthy HIV-seronegative men
###end article-title 97
###begin article-title 98
###xml 63 91 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
###end article-title 98
###begin article-title 99
###xml 125 128 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients
###end article-title 99
###begin article-title 100
###xml 107 110 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia
###end article-title 100
###begin article-title 101
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
###end article-title 101
###begin article-title 102
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials
###end article-title 102
###begin article-title 103
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
###end article-title 103
###begin article-title 104
Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals
###end article-title 104
###begin article-title 105
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 61 64 <span type="species:ncbi:9606">men</span>
The metabolic effects of lopinavir/ritonavir in HIV-negative men
###end article-title 105
###begin article-title 106
###xml 33 36 <span type="species:ncbi:9606">men</span>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Alterations in lipid kinetics in men with HIV-dyslipidemia
###end article-title 106
###begin article-title 107
Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study
###end article-title 107
###begin article-title 108
Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility
###end article-title 108
###begin article-title 109
Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII
###end article-title 109
###begin article-title 110
The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism?
###end article-title 110
###begin article-title 111
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
###end article-title 111
###begin article-title 112
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 69 84 <span type="species:ncbi:10090">transgenic mice</span>
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
###end article-title 112
###begin article-title 113
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 48 63 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
###end article-title 113
###begin article-title 114
An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms
###end article-title 114
###begin article-title 115
Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia
###end article-title 115
###begin article-title 116
Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes
###end article-title 116
###begin article-title 117
Black-white differences in serum lipids and lipoproteins in Evans County
###end article-title 117
###begin article-title 118
Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994)
###end article-title 118
###begin article-title 119
Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey
###end article-title 119
###begin article-title 120
Sources of variability in genetic association studies: Insights from the analysis of hepatic lipase (LIPC)
###end article-title 120
###begin article-title 121
Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations
###end article-title 121
###begin article-title 122
The effects of scale: Variation in the APOA1/C3/A4/A5 gene cluster
###end article-title 122
###begin article-title 123
DNA polymorphic patterns and haplotype arrangements of the apo A-1, apo C-III, apo A-IV gene cluster in different ethnic groups
###end article-title 123
###begin article-title 124
Variable effects of the APOC3-482C > T variant on insulin, glucose, and triglyceride concentrations in different ethnic groups
###end article-title 124
###begin article-title 125
Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia
###end article-title 125
###begin article-title 126
Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake, and plasma lipoproteins
###end article-title 126
###begin article-title 127
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
###end article-title 127
###begin article-title 128
Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous
###end article-title 128
###begin article-title 129
###xml 67 70 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Participation in research and access to experimental treatments by HIV-infected patients
###end article-title 129
###begin article-title 130
Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24
###end article-title 130
###begin article-title 131
New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia
###end article-title 131
###begin article-title 132
###xml 48 53 <span type="species:ncbi:9606">human</span>
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
###end article-title 132
###begin article-title 133
Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene
###end article-title 133
###begin article-title 134
Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins
###end article-title 134
###begin article-title 135
###xml 141 149 <span type="species:ncbi:9606">children</span>
Hypertriglyceridemia and the apolipoprotein CIII gene locus: Lack of association with the variant insulin response element in Italian school children
###end article-title 135
###begin article-title 136
Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia
###end article-title 136
###begin article-title 137
Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking status
###end article-title 137
###begin article-title 138
###xml 135 138 <span type="species:ncbi:9606">men</span>
Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men
###end article-title 138
###begin article-title 139
Interaction between smoking and the Sstl polymorphism of the apo C-III gene determines plasma lipid response to diet
###end article-title 139
###begin article-title 140
Loci for CETP, LPL, LIPC, and APOC3 affect plasma lipoprotein size and sub-population distribution in Hispanic and non-Hispanic white subjects: The Columbia University BioMarkers Study
###end article-title 140
###begin article-title 141
###xml 45 50 <span type="species:ncbi:9606">human</span>
Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo
###end article-title 141
###begin article-title 142
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
###end article-title 142
###begin article-title 143
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy naive patients infected with HIV-1
###end article-title 143
###begin article-title 144
A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation
###end article-title 144
###begin article-title 145
Mixed modeling to characterize genotype-phenotype associations
###end article-title 145
###begin article-title 146
"Racial" differences in genetic effects for complex diseases
###end article-title 146
###begin article-title 147
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Reversal of atherogenic lipoprotein profile in HIV-1-infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
###end article-title 147
###begin title 148
Abbreviations
###end title 148
###begin p 149
AIDS Clinical Trial Group
###end p 149
###begin p 150
apolipoprotein
###end p 150
###begin p 151
antiretroviral therapy
###end p 151
###begin p 152
cardiovascular
###end p 152
###begin p 153
confidence interval
###end p 153
###begin p 154
efavirenz
###end p 154
###begin p 155
high-density lipoprotein cholesterol
###end p 155
###begin p 156
interquartile range
###end p 156
###begin p 157
linkage disequilibrium
###end p 157
###begin p 158
nelfinavir
###end p 158
###begin p 159
protease inhibitor
###end p 159
###begin p 160
ritonavir
###end p 160
###begin p 161
single nucleotide polymorphism
###end p 161
###begin p 162
triglyceride
###end p 162
###begin title 163
Figures and Tables
###end title 163
###begin title 164
Predicted TG Levels for PI- and Non-PI-Exposed Individuals by Race/Ethnicity
###end title 164
###begin p 165
Estimated fold increases (95% CI) for non-RTV-containing PI regimen (compared to no current PI exposure) are 0.97 (0.80, 1.18) for White/non-Hispanics, 1.39section sign (1.02, 1.89) for Black/non-Hispanics, and 1.23 (0.89, 1.69) for Hispanics. Estimated fold increases (95% CI) for RTV-containing PI regimen (compared to no current PI exposure) are 1.35section sign (1.00, 1.83) for White/non-Hispanics, 1.62 (0.75, 3.50) for Black/non-Hispanics, and 1.51 (0.91, 2.52) for Hispanics. section sign Indicates significantly different than 1.0-fold at the 0.05 level.
###end p 165
###begin title 166
Predicted TG Levels for PI- and Non-PI-Exposed Hispanics by Composite ApoC-III Genotype Variable
###end title 166
###begin p 167
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*ApoCIII-482 (CT/TT), -455 (TC/CC), and/or SstI (3238) CG/GG. The negative effect of PI exposure on TGs is greatly attenuated (56% less) among Hispanics with one or more apoC-III variant compared to Hispanics with the wild-type genotype at these loci (95% CI = [0.32, 0.97], p-value = 0.04.)
###end p 167
###begin title 168
Lipid Profiles by Race/Ethnicity, Gender, and PI Exposure
###end title 168
###begin title 169
Multivariable Adjusted Association of Race/Ethnicity and PI Exposure with Lipid Outcomes
###end title 169
###begin title 170
Estimated ApoC-III Haplotype Frequencies by Race/Ethnicity
###end title 170
###begin title 171
Interaction Effects of Variants in ApoC-III /ApoA-I with PI on Plasma TG by Race/Ethnicity
###end title 171
###begin title 172
Predicted TG Levels by Genotype, Race/Ethnicity, and PI Exposure
###end title 172
###begin p 173
###xml 143 148 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Citation: Foulkes AS, Wohl DA, Frank I, Puleo E, Restine S, et al. (2006) Associations among race/ethnicity, apoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med 3(3): e52.
###end p 173

